AHA PREVENT, ASCVD PCE, and WHO HEARTS are exclusively validated for Primary Prevention. If your patient has already suffered a myocardial infarction, stroke, or has peripheral arterial disease, calculating a 10-year risk score is algorithmically negligent. They have proven disease and automatically require aggressive secondary prevention (High-Intensity Statin) regardless of age or lipid levels.

The 2024 AHA PREVENT equations introduce the Cardio-Kidney-Metabolic (CKM) Staging system. It formally recognises that excess adiposity (Stage 1), metabolic risk factors like hypertension and CKD (Stage 2), and subclinical atherosclerosis (Stage 3) are an interconnected continuum. This tool automatically calculates the CKM Stage based on your inputs. Use this to shift your mindset from purely "lowering cholesterol" to holistic cardio-renal protection (e.g., prompting SGLT2i or GLP-1 RA use).

Order a CAC scan when your patient falls in the borderline or intermediate risk zone and you are genuinely uncertain about starting a statin. A CAC of zero in a non-diabetic patient is your strongest reason to defer pharmacotherapy and recheck in 5 years. A CAC ≥ 100 ends the discussion: start the statin. Do NOT order CAC in patients who already have established ASCVD or are clearly high-risk. It will not change management and adds unnecessary radiation.

A 45-year-old Indian male with an LDL of 110 mg/dL and an ASCVD score of 4% looks "low risk" on paper. However, South Asians develop myocardial infarction a decade earlier, at lower LDL thresholds, and with more vulnerable plaques. Always evaluate Non-HDL-C, which captures all atherogenic particles including VLDL remnants. In South Asian patients with high triglycerides, LDL-C can be misleadingly "normal" while Non-HDL-C reveals the true atherogenic burden.

Relying solely on LDL-C can be highly misleading. Apolipoprotein B (ApoB) provides a direct measure of the total number of atherogenic particles, while ApoA1 reflects protective HDL capacity. An ApoB/ApoA1 ratio > 0.9 in men (or > 0.8 in women) signifies a highly atherogenic phenotype requiring aggressive intervention. Lipoprotein(a) is highly atherogenic and heavily genetically determined. Values > 50 mg/dL indicate a profound risk of premature ASCVD. Standard statin therapy does not lower Lp(a); you must respond by driving the patient's ApoB/Non-HDL-C down to exceedingly low targets to mitigate the aggregate risk.